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Abstract
Background:  Surgical treatment of peripheral vascular disease (PVD) in dialysis patients is
controversial.
Methods: We examined the post-operative morbidity and mortality of surgical revascularization
or amputation for PVD in a retrospective analysis of United States Renal Data System. Propensity
scores for undergoing amputation were derived from a multivariable logistic regression model of
amputation.
Results: Of the Medicare patients initiated on dialysis from Jan 1, 1995 to Dec 31, 1999, patients
underwent surgical revascularization (n = 1,896) or amputation (n = 2,046) in the first 6 months
following initiation of dialysis were studied. In the logistic regression model, compared to
claudication, presence of gangrene had a strong association with amputation [odds ratio (OR) 19.0,
95% CI (confidence interval) 13.86–25.95]. The odds of dying within 30 days and within1 year were
higher (30 day OR: 1.85, 95% CI: 1.45–2.36; 1 yr OR: 1.46, 95% CI: 1.25–1.71) in the amputation
group in logistic regression model adjusted for propensity scores and other baseline factors.
Amputation was associated with increased odds of death in patients with low likelihood of
amputation (< 33rd percentile of propensity score) and moderate likelihood of amputation (33rd to
66th percentile) but not in high likelihood group (>66th percentile). The number of hospital days in
the amputation and revascularization groups was not different.
Conclusion: Amputation might be associated with higher mortality in dialysis patients. Where
feasible, revascularization might be preferable over amputation in dialysis patients.
Background
Nineteen percent of incident dialysis patients have
peripheral vascular disease (PVD) [1]. Amputation rate
among diabetic dialysis patients is ten times that of dia-
betic population at large [2]. Over 2-years of follow-up,
2.9% of dialysis patients underwent amputation [3] and
in a surgical series, 23% of patients who underwent ampu-
tation were on dialysis [4]. Thus, peripheral vascular dis-
ease is common and carries considerable morbidity and
mortality in dialysis patients. However, the surgical
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management of PVD in the dialysis population remains
controversial. It has been suggested by some authors that
because of delayed wound healing and prolonged hospi-
talization, primary amputation is preferred over revascu-
larization for PVD in dialysis patients while others have
argued that a careful selection of dialysis patients for
revascularization might result in acceptable outcomes [5-
12]. In this study, we examined the post-operative mor-
bidity and mortality of surgical revascularization or
amputation for PVD in a large cohort of Medicare dialysis
patients.
Methods
The study design was a retrospective analysis of Medicare
patients in the United States Renal Data System (USRDS).
Study population
Of the Medicare patients initiated on dialysis from Jan 1,
1995 to Dec 31, 1999, those who underwent surgical
revascularization or amputation within 6 months of initi-
ation of dialysis were studied. Because information on
functional status (shown to be an important predictor of
post-surgical outcomes in PVD in dialysis patients) [6]
and nutritional status (serum albumin and BMI) were
only available at initiation of dialysis, only patients who
underwent the surgical procedures in the first 6 months of
dialysis were included. The study included only those
amputated patients with known PVD, as amputations for
diabetic foot are also performed for non-ischemic ulcers.
Patients with duplicate entries, previous renal replace-
ment therapies, age < 18 years of age and incomplete fol-
low-up information were excluded. In addition, patients
with missing data on serum albumin, height and weight
were excluded.
Data assembly
The Medical Evidence (Form 2728) form is the mandatory
form gathered by the Centers for Medicare and Medicaid
on patients initiated on chronic maintenance dialysis in
the US. The Form 2728 data on demographics (age, gen-
der and race), cause of ESRD (diabetes or others), insur-
ance status (Medicare or non-Medicare), comorbid
conditions (coronary artery disease, cerebrovascular dis-
ease, peripheral vascular disease, congestive heart failure,
malignancy, acquired immunodeficiency syndrome,
chronic lung disease), smoking, serum albumin, height,
weight and functional ability were used in this analysis
[13]. Body mass index (kg/m2) was calculated from height
and weight.
Definitions of peripheral vascular disease and procedures
A patient with reported PVD in the Medical Evidence form
or ICD-9-CM codes 440.20–440.24, 440.29, 440.30–
440.32, 443.81, 443.9 or 785.4 from initiation of dialysis
to the first hospitalization for amputation or surgical
revascularization was considered to have PVD. The clini-
cal indication for the surgical intervention was identified
from ICD-9-CM codes as intermittent claudication
(440.21), resting pain (440.22), ulcer (440.23, 707.10–
707.15, 707.19), gangrene (440.24 or 785.4) or other/
unknown (not any of the above ICD-9-CM codes). The
first procedure (amputation or surgical revascularization)
that occurred after initiation of dialysis was identified
from Medicare billing data. Amputations were defined as
ankle or below amputations (procedure codes 84.12 –
84.15), knee or below amputations (procedure codes
84.15 – 84.16) and above knee amputations (procedure
codes 84.17 – 84.19). Amputations of toes (84.11) were
not included. Proximal bypass procedures involving the
aorta-iliac-femoral-popliteal vessels were identified using
procedure code 39.29. Distal bypass procedures were
identified using procedure code 39.25, "other peripheral
vascular bypass surgery, other than aorta-iliac-femoral
bypass to the tibial, peroneal or dorsal artery." This code
also designates vascular bypass procedures in the upper
limb. However, in an earlier study, only three did not have
a distal lower-limb bypass procedure in over 300 hospital
discharge records with the procedure code 39.25 [14].
Data on PVD-related procedures before initiation of dial-
ysis were unavailable in the USRDS and were not included
in the present study.
Outcomes
Follow-up duration, mortality and transplantation data
were obtained from the United States Renal Data System
treatment history, claims and patients files. Patients were
tracked until loss to follow-up, transplantation, death, or
the administrative censor date of December 31, 1999.
Cardiovascular death was defined as cause of death coded
in the USRDS death notification form as myocardial inf-
arction, atherosclerotic heart disease, cardiomyopathy,
arrhythmia, valvular heart disease, cerebrovascular dis-
ease and mesenteric infarction. The number of hospital
days (including the index hospitalization) in the first 6
months after the procedure and 30-day and 1-year post-
operative mortality were the outcomes of interest.
Statistical analysis
Baseline characteristics of amputation and revasculariza-
tion groups were not statistically examined because of the
large sample size. The propensity score method was used
to account for the confounding that arises because
patients whom underwent amputation were not other-
wise equivalent to patients in whom surgical revasculari-
zation was performed. Stepwise logistic regression model
was employed to select patient characteristics independ-
ently associated with amputation. Variables examined in
the logistic regression model were demographics (age, sex,
race), dialysis modality, comorbid conditions (diabetes,
coronary artery disease, congestive heart failure,BMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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cerebrovascular disease and malignancy), clinical indica-
tions (intermittent claudication, resting pain, ulcer, gan-
grene or other/unknown), hematocrit, nutritional status
(BMI and serum albumin) and functional status (required
assistance to transfer or ambulate). On the basis of the
value of each independent factor multiplied by its beta
coefficient, subjects were ranked with respect to their pre-
dicted probability (propensity score) of undergoing
amputation versus revascularization [15,16].
Thirty-day and one-year mortality in amputation and
revascularization groups were examined in a multivaria-
ble logistic regression model adjusted for propensity
scores, demographics (age, sex, race), dialysis modality,
comorbid conditions (diabetes, coronary artery disease,
congestive heart failure, cerebrovascular disease and
malignancy), clinical indications (intermittent claudica-
tion, resting pain, ulcer, gangrene or other/unknown),
hematocrit, nutritional status (BMI and serum albumin)
and functional status (requires assistance to transfer or
ambulate). Similarly, we also examined thirty-day and
one-year cardiovascular mortality in amputation versus
revascularization groups in a multivariable logistic regres-
sion model.
Differences in hospital days in the first six months post-
procedure were compared between revascularization and
amputation groups by analysis of covariance adjusted for
variables described in the above mortality analysis. In
addition, the duration of follow-up was used as a covari-
ate to account for shorter duration of follow-up in those
who died. Hospital days were log transformed to meet
normality assumptions.
Sensitivity analyses
This study relied on ICD-9 CM codes for indications
(intermittent claudication, rest pain, ulcer, gangrene or
other/unknown) for amputation. As presence of gangrene
is a strong indication for amputation and if ICD-9 CM
codes reliably identified those patients with gangrene, a
logistic regression model that included clinical indica-
tions would better predict amputations than another
model that did not include clinical indications. This was
tested by examining the c statistic of receiver-operator
characteristic (ROC) curves of logistic regression models
that included and excluded clinical indications.
It could also be argued that patients who underwent
amputation were treated only at advanced stage (gan-
grene) of peripheral vascular disease and if amputations
were performed at earlier stages, the outcomes post-
amputation would be superior. If advanced peripheral
vascular disease (gangrene) was associated with higher
likelihood of undergoing amputation, patients with lower
likelihood of undergoing amputation (higher likelihood
for undergoing revascularization) would have had less
advanced peripheral vascular disease. Thus, examination
of amputation versus revascularization outcomes in
patients at low, moderate and high likelihood of undergo-
ing amputation might reveal better outcomes post-ampu-
tation in the low likelihood group and worse outcomes in
the high likelihood group. These three likelihood groups
were created using the 33rd and 66th percentiles of propen-
sity scores as cut-points.
As procedure code 39.25 might have included upper limb
revascularization procedures, analyses were repeated with
including only procedure code 39.29 (proximal bypass
procedures involving the aorta-iliac-femoral-popliteal
vessels).
Results
Of the 317,533 patients initiated on dialysis from January
1, 1995 to December 31, 1995, there were 5,916 patients
who underwent amputation or revascularization in first
six months of initiating dialysis. Patients with missing
data on demographics or comorbidity (n = 436) and
nutritional status (serum albumin or BMI) (n = 1,153)
were excluded. There were 279 patients who underwent
amputation and revascularization procedures in the same
admission. Some of these patients might have undergone
revascularization first followed by an amputation in the
same limb and others might have undergone amputation
in one limb and revascularization in the other limb. Since
ICD-9-CM codes do not provide information on which
side the procedure was performed, we could not identify
the sequence of events and therefore, excluded these
patients. Further, amputations are also performed for
indications other than peripheral vascular disease and we
excluded 106 amputation patients in whom a diagnosis of
peripheral vascular disease could not be established based
on Medical Evidence forms or ICD-9-CM codes. Thus,
3,942 patients who underwent amputation (n = 2,046) or
revasularization (n = 1,896) were studied.
The mean age of the entire cohort was 70 ± 9 years, 64.2%
had diabetes and 92.6% were on hemodialysis. There
were 493 (12.5%) deaths within 30 days of the procedure,
of which 390 (79.1%) occurred in patients with gangrene.
1,950 patients (49.5%) died in the first year following the
surgical procedure.
Table 1 summarizes the baseline clinical characteristics in
amputation or revascularization groups. Surprisingly,
amputation group was younger than the revascularization
group. Compared to revascularization group, amputated
group had greater prevalence of diabetes (74% v 53%),
congestive heart failure (53% v 49%), cerebrovascular dis-
ease (19% v 15%) and required assistance to transfer (7%
v 2%) or ambulate (17% v 6%). In multivariable logisticBMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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Table 1: Baseline characteristics of the study population by procedure groups
Amputated Revascularized
N = 3942 N = 2046 N= 1896
Demographics
Age in years, mean ± SD 69.4 ± 9.7 71.5 ± 8.1
Male Gender, n (%) 1148 (56) 1097 (58)
Race, n (%)
Caucasians 1333 (65) 1464 (77)
African Americans 630 (31) 370(20)
Other 83 (4) 62 (3)
ESRD
Diabetes as cause of ESRD, n (%) 1518 (74) 1011 (53)
Dialysis Modality, n (%)
HD 1875 (92) 1777 (94)
PD 171 (8) 119 (6)
Comorbidity
Coronary disease, n (%) 1077 (53) 893 (47)
Congestive heart failure, n (%) 1076 (53) 934 (49)
Cerebrovascular disease, n (%) 380 (19) 289 (15)
Smoker, n (%) 94 (5) 138 (7)
Cancer, n (%) 74 (4) 91 (5)
Clinical Indications
Intermittent claudication 6 (0.3) 91 (4.8)
Resting pain 13 (0.6) 97 (5.1)
Ulcer 31 (1.5) 225 (11.9)
Gangrene 1850 (90.4) 755 (39.8)
Other/unknown 146 (7.1) 728 (38.4)
Nutrition
BMI, mean ± SD 25.3 ± 5.6 24.7 ± 5.2
Serum Albumin, mean ± SD 3.0 ± 0.6 3.2 ± 0.6
Functional Status
Require assistance to transfer, n (%) 139 (7) 30 (2)
Require assistance to ambulate, n (%) 342 (17) 113 (6)
Other
Hematocrit, mean ± SD 27.8 ± 7.0 28.5 (6.8)
Table 2: Variables significantly associated with amputation in a multivariate logistic model
Covariate Odds Ratio 95% confidence interval P-value
5 year increase in age 0.90 0.86 – 0.94 <0.001
African American v Caucasian 1.52 1.27 – 1.81 <0.001
Diabetes as cause of ESRD 1.66 1.40 – 1.96 <0.001
Peritoneal dialysis 1.54 1.14 – 2.09 0.005
Gangrene v claudication 19.0 13.86 – 25.95 <0.001
Indication for amputation unknown/other v claudication 1.53 1.08 – 2.18 0.018
Each g/dl increase in serum albumin 0.73 0.64 – 0.83 <0.001
Needs assistance to transfer 1.72 1.00 – 2.94 0.049
Needs assistance to ambulate 2.59 1.89 – 3.53 <0.001BMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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regression model (Table 2), presence of gangrene had the
strongest association with amputation. Indeed, the area
under the ROC curve (Fig 1a) for the logistic regression
model that included all variables except clinical indica-
tions was only 0.68 indicating low discrimination of these
variables in correctly identifying patients whom under-
went amputation. When clinical indication was included
in the model, the area under the ROC curve (Fig 1b)
improved to 0.82 indicating excellent discrimination in
identifying patients whom underwent amputation.
There were 165 (8.7%) deaths within 30 days and 942
(49.7%) deaths within 1 year in the revascularization
group compared to 328 (16.0%) deaths within 30 days
and 1,275 (62.3%) within 1 year in the amputation
group. In unadjusted logistic regression analysis, amputa-
tion group had 2 fold higher odds of dying within 30 days
of the procedure compared to the revascularization group
(Table 3). When adjusted for propensity scores and clini-
cal variables, amputated group still had 85% higher odds
of dying within 30 days (Table 3). In subgroup analyses
by likelihood of undergoing amputation, amputation
procedure was associated with the highest odds of dying
within 30 days in patients with low likelihood of under-
going amputation, reduced but still significant odds in
patients with moderate likelihood of undergoing amputa-
tion and non-significant increase in patients with high
likelihood of undergoing amputation (Table 3). Similar
results were seen when post-operative mortality was
examined using follow-up of 1 year. After adjusting for
propensity scores, demographics, dialysis modality,
comorbid conditions, clinical indications, hematocrit,
nutritional and functional status, the amputation group
had 46% higher odds of cardiovascular death within 30
days (OR: 1.46, 95% CI: 1.25–1.71) and 18% higher odds
of cardiovascular death within 1 year (OR: 1.18, 95% CI:
1.00–1.39).
Receiver-operator characteristic curve of amputation Figure 1
Receiver-operator characteristic curve of amputa-
tion. Legend: ROC curves of amputation without clinical 
indication in the model (Figure 1A) and with clinical indica-
tion in the model (Figure 1B)
A
B
Table 3: 30-day and 1 year post-procedure mortality in amputation versus revascularization groups in the entire cohort and subgroups 
of likelihood of amputation
30 day mortality 1 year mortality
Odds ratio* (95%CI) Odds ratio* (95%CI)
Entire cohort (n = 3942)
Unadjusted 2.00 (1.64–2.44) 1.67 (1.48–1.90)
Adjusted** 1.85 (1.45–2.36) 1.46 (1.25–1.71)
Subgroup analyses by likelihood for amputation***
Low likelihood group (n = 1314) 1.85 (1.06–3.23) 1.61 (1.14–2.26)
Moderate likelihood group (n = 1314) 2.05 (1.47–2.87) 1.55 (1.22–1.96)
High likelihood group (n = 1314) 1.56 (0.91–2.21) 1.23 (0.92–1.63)
*reference revascularization group
**adjusted for propensity scores, demographics (age, sex, race), dialysis modality, comorbid conditions (diabetes, coronary artery disease, 
congestive heart failure, cerebrovascular disease and malignancy), clinical indications (intermittent claudication, resting pain, ulcer, gangrene or 
other/unknown), hematocrit, nutritional status (BMI and serum albumin) and functional status (required assistance to transfer or ambulate).
***adjusted for all above variables except propensity scoreBMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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Clinical indication for the procedure was a predictor of
post-operative mortality. There were 6 (6.2%), 12
(10.9%), 16 (6.3%), 390 (15.0%) and 69 (7.9%) deaths
associated with intermittent claudication, rest pain, ulcer,
gangrene and other/unknown indications respectively. In
the above multivariable logistic regression model of mor-
tality in the entire cohort, compared to intermittent clau-
dication, presence of gangrene was associated with 54%
higher odds (OR 1.54, 95% CI 1.18 – 2.01, p = 0.002) of
death. Presence of rest pain, ulcer or other/unknown indi-
cations were not associated with increased risk of death in
the multivariable model.
The median number of days spent in the hospital were 28
in the amputation group and 26 in the revascularization
group. In unadjusted analysis, these differences were sig-
nificant (p = 0.003, adjusted R2 = 0.06 for the model).
However, these differences were non-significant (p = 0.33,
adjusted R2 = 0.08 for the model) when adjusted for pro-
pensity scores, demographics (age, sex, race), dialysis
modality, comorbid conditions (diabetes, coronary artery
disease, congestive heart failure, cerebrovascular disease
and malignancy), clinical indications (intermittent clau-
dication, resting pain, ulcer, gangrene or other/
unknown), hematocrit, nutritional status (BMI and serum
albumin) and functional status (requires assistance to
transfer or ambulate).
Among the revascularization group, 1,701 had ICD-9 CM
code 39.29, 207 had ICD-9 CM code 39.25 and 12
patients had both codes. When analyses were repeated
with revascularization including only ICD-9 CM code
39.29 (proximal bypass procedures involving the aorta-
iliac-femoral-popliteal vessels), the results were similar
(data not shown).
Discussion
About 19% of incident dialysis patients have a clinical
diagnosis of peripheral vascular disease (PVD)[1]. In the
USRDS Dialysis Morbidity and Mortality Study Waves III
and IV, 6.1% of diabetic hemodialysis patients and 0.8%
of non-diabetic hemodialysis patients underwent lower
extremity amputation [3] over two years. When compared
to general population, outcomes after revascularization or
amputation for PVD in dialysis patients were inferior
[8,17]. The problems with revascularization in PVD in
dialysis patients include high perioperative and 1-year
mortality, decreased wound healing, loss of limb despite
patent graft and prolonged hospital stay and poor rehabil-
itation. Therefore, liberal use of primary amputation for
peripheral vascular disease was suggested in dialysis
patients by some authors [5]. However, careful patient
selection for revascularization in dialysis patients might
result in acceptable outcomes. Baele et al [6] reported in a
series of 44 hemodialysis patients who underwent revas-
cularization a two-year survival rate of 48%, perioperative
mortality of 9%, primary graft patency at 1 year and 2
years of 71% and 63% and limb salvage at 1 year and 2
years of 70% and 52%. In that study, an aggressive
approach to limb salvage was favored when patients were
found to be ambulatory or able to use the affected extrem-
ity for purposes of weight bearing or transfer. Attempted
limb salvage was not advocated for patients who were
chronically bedridden or those with uncontrolled infec-
tion or tissue necrosis precluding a reasonable expectation
of limb salvage. Thus, extensive tissue necrosis in non-
weight bearing limb and pre-operative infection might be
indications for primary amputation.
The results of the current study (Table 2) show that while
black race, peritoneal dialysis, diabetes and poor func-
tional and nutritional status were associated with
amputation, the strong association of presence of gan-
grene and younger age with amputation are the most strik-
ing. As presence of gangrene was a strong indication for
amputation rather than revascularization, either by
patient preference or surgical determination of high peri-
operative mortality risk, older dialysis patients with gan-
grene might have never started dialysis or withdrawn from
dialysis rather than undergo amputation. Thus, amputa-
tion might have been performed only in younger patients
with gangrene and not in older patients with gangrene.
This might explain the association of younger age with
amputation.
As shown in Figures 1a and 1b, presence of gangrene was
the overwhelming factor associated with amputation. In
an earlier analysis of prevalent hemodialysis patients in
the Dialysis Morbidity and Mortality Study Waves 3 and 4
data, elevated serum phosphorus was also found to be a
predictor of amputation [3]. Because data on serum phos-
phorus were unavailable in the Medical Evidence form,
we could not examine the association of serum phospho-
rus with amputation in this study. However, a c statistic of
0.82 (Fig 1b) indicates that the factors considered in this
study (Table 2) explained most of the variations in the
clinical decision of amputation versus revascularization.
There were 8.7% deaths within 30 days in the revasculari-
zation group compared to 16.0% deaths in the amputa-
tion group. These results are comparable to earlier reports
on peri-operative mortality of dialysis patients who
underwent amputation or revascularization
[10,12,18,19]. In unadjusted logistic regression analysis,
amputation group had 2 fold higher odds of dying within
30 days of the procedure compared to the revasculariza-
tion group (Table 3). There are several possible explana-
tions for this observation. First, selection of healthier
patients with better nutrition and functional status and
without significant tissue damage probably resulted inBMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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lower 30-day mortality in the revascularized group. How-
ever, adjusting for the above factors did not completely
eliminate this association. Second, it might be argued that
the clinical indications for amputation versus revasculari-
zation could explain the differences in outcomes. How-
ever, even after using propensity scores to control for
confounding by indication, amputation group still had
higher mortality. In this retrospective observational study
of Medicare data, unmeasured factors that influenced the
decision to perform amputation might invalidate the pro-
pensity score approach. However, as noted above, a c sta-
tistic of 0.82 indicates that the factors considered in this
study explained most of the variations associated with the
decision to perform amputation. Thus, it is unlikely that
other very significant factors that influenced the decision
to perform amputation were not considered in this study.
Third, it is possible that amputation was only performed
in advanced stages of peripheral vascular disease and
amputation in earlier stages might have resulted in supe-
rior outcomes. If this were true, as explained in the meth-
ods section, amputation would be expected to have better
outcomes in patients at low likelihood for amputation.
This was not the case as shown in Table 3. In fact, ampu-
tation in patients with low and moderate likelihood for
amputation was associated increased mortality and not in
the high likelihood group. These results suggest that
undergoing amputation rather than revascularization in
healthier dialysis patients with lesser tissue damage might
actually increase mortality. Thus, our results support the
approach suggested by Baele et al that revascularization is
feasible and might be the preferred method of treatment
of symptomatic PVD in carefully selected dialysis patients.
Therefore, symptomatic peripheral vascular disease in
dialysis patients should not automatically result in
amputation.
One of the arguments in favor of amputation which
results in loss of limb over revascularization that might
save the limb is that revascularization is associated with
prolonged hospitalization whereas amputation results in
shorter hospital stay, quicker recovery and better rehabili-
tation. However, in this large study, the median (inter-
quartile range) number of hospital days in amputation
and revascularization groups were 28 (6–48) and 26 (14–
44) days respectively. Thus, these data do not support the
contention that amputation is associated with lower hos-
pital stay. Further, in many studies only about 25%
patients post-amputation were ambulatory [4,20]. Thus, it
does not appear that amputation would result in shorter
hospital stay, quicker recovery and better rehabilitation.
A striking feature of the current study is the association of
both revascularization and amputation with very high 30-
day post-operative mortality in dialysis patients. These
results emphasize the importance of preventing or slow-
ing down the development of advanced PVD that requires
surgical interventions. Therefore, in the absence of evi-
dence to the contrary, aggressive medical therapy of PVD
used in the general population should be adopted to the
dialysis population. Thus, in all dialysis patients with PVD
(including asymptomatic patients), smoking cessation,
maintenance of LDL cholestrol < 100 mg/dl, maintenance
of glycosylated HbA1c < 7.0 mg/dl in diabetics, control of
blood pressure, use of ACE inhibitors and antiplatelet
agents (aspirin or clopidogrel) should be considered [21].
There are several limitations to our study. First, even
though the use of propensity scores might have reduced
indication bias, residual bias might still exist. Therefore,
all the analyses should be interpreted with caution. Sec-
ond, clinical data such as the level and extent of arterial
stenosis, extent of tissue necrosis, presence or absence of
infection were not available. However, it might be reason-
able to assume that patients with extensive tissue necrosis
and severe infections underwent amputations rather than
revascularization. Thus, it could still be inferred that a
careful selection for revascularization of patients without
severe disease might result in acceptable outcomes and
save the limb. On the other hand, information on quality
of life pre and post-procedures were also not available. It
is possible that major amputation resulted in significant
loss in quality of life and successful revascularization
improved quality of life. Third, the presence or absence of
gangrene was identified from ICD-9 CM codes. It is possi-
ble that the strong association of gangrene with amputa-
tion was not because gangrene was an indication for
amputation rather patients whom underwent amputation
were coded to have gangrene. We believe this is unlikely
because 79% of all deaths within 30 days of procedure
occurred in patients with an ICD-9-CM diagnosis of gan-
grene and it was also associated with 54% higher odds of
death in the multivariable model. Fourth, ICD-9-CM
codes on clinical indication were not present in 874
(22.2%) patients and thus this information is unavailable
in those patients. However, as the death rate of these
patients were not as high of those patients with gangrene,
it is quite likely that the ICD-9-CM codes on clinical indi-
cation were not entered in patients without gangrene.
Fifth, even though small, single center studies could
obtain more information on primary graft patency and
limb salvage, in the larger national sample of Medicare
patients these data are unavailable. Thus, larger studies of
national sample of Medicare patients and smaller single
center studies complement each other. Finally, the limita-
tions of this study include those of retrospective studies
that use existent databases. Since only patients on Medi-
care defined the study population, it is possible that
patients younger than 65 years who were not yet covered
by Medicare were excluded introducing some selection
bias. Further, the medical evidence form (form 2728) hasBMC Nephrology 2005, 6:3 http://www.biomedcentral.com/1471-2369/6/3
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been shown to have intermediate sensitivity but high spe-
cificity for comorbid conditions reported in the form [22].
Conclusion
We conclude that amputation might carry significant mor-
bidity and mortality in dialysis patients compared to
revascularization procedures. More importantly, further
studies are warranted to determine whether early diagno-
sis and aggressive medical therapy decrease the need for
revascularization or amputation in dialysis patients with
PVD.
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